Safety and Efficacy of VDPHL01 in Males and Females with AGA

Recruiting

Phase 2

Safety and Efficacy of VDPHL01 in Males and Females with AGASafety and Efficacy of VDPHL01 in Males and Females with AGA

Sponsor:

Veradermics, Inc.

Code:

NCT06527365

Conditions

Androgenetic Alopecia

AGA

Male Pattern Baldness

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

VDPHL01

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-02. This information was provided to ClinicalTrials.gov by Veradermics, Inc. on 2025-03-25.